Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2025 | $60.00 | Buy | Chardan Capital Markets |
| 3/19/2025 | $76.00 | Overweight | Piper Sandler |
| 1/10/2025 | $72.00 | Overweight | Piper Sandler |
| 10/11/2024 | $50.00 | Buy | Rodman & Renshaw |
| 11/1/2021 | $9.00 | Buy | HC Wainwright & Co. |
WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "us" and "our") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, in collaboration with Excel Diagnostics and Nuclear Oncology Center ("EDNOC"), a premier diagnostic medical imaging and therapeutic nuclear medicine center, today announced that the physician-sponsored Expanded Access Program ("EAP") for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration ("FD
WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the close of U.S. equity markets on June 27, 2025. The inclusion follows the initial announcement on Friday, May 23, and the subsequent update on Friday, May 30, 2025, in connection with the annual reconstitution of the Russell U.S. Indexes. The Russell 2000® Index tracks the performance of the small-c
WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025, a leading global conference in liver disease. The data support ALXN1840 as a potential treatment for Wilson disease
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
Chardan Capital Markets initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $60.00
Piper Sandler resumed coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $76.00
Piper Sandler initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $72.00
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
4 - Monopar Therapeutics (0001645469) (Issuer)
DEFA14A - Monopar Therapeutics (0001645469) (Filer)
SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
10-Q - Monopar Therapeutics (0001645469) (Filer)